Literature DB >> 6265902

On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.

H S Allaudeen, J W Kozarich, J R Bertino, E De Clercq.   

Abstract

Bromovinyldeoxyuridine (BVdUrd) is a potent antiherpesvirus compound with low cytotoxicity. To gain an insight into its selectivity and mechanism of inhibition, we chemically synthesized the 5'-triphosphate of BVdUrd, BVdUTP, and tested its effect on the activities of DNA polymerases [DNA nucleotidyltransferase (DNA directed), EC 2.7.7.7] of two herpesviruses--i.e., herpes simplex virus type 1 (HSV-1) and Epstein-Barr virus (EBV)--as well as cellular DNA polymerases alpha, beta, and gamma. The effects on the DNA polymerases were determined under assay conditions optimal for the individual polymerases. We found that the BVdUTP was considerably more inhibityory to the utilization of dTTP by the HSV-1 DNA polymerase then by the cellular DNA polymerases. For instance, as little as 1 microM BVdUTP inhibited the utilization of dTTP by HSV-1 DNA polymerase 50%, whereas the same concentration inhibited the DNA polymerase alpha and the DNA polymerase beta activities only 9% and 3%, respectively. The BVdUTP inhibited DNA synthesis by competing with the natural substrate, dTTP. The Km for dTTP and the Ki for the BVdUTP of the HSV-1 DNA polymerase were 0.66 and 0.25 microM, respectively. Kinetic analyses with the DNA polymerases alpha and beta and the EBV DNA polymerase also reflected a similar difference in sensitivity between the HSV-1 enzyme and other enzymes. Increasing the concentration of either the DNA template or the enzyme in the reaction mixture did not bring about a significant change in the extent of inhibition. Preincubation of the inhibitor with the enzyme was not necessary for inhibition. Studies on time course of inhibition revealed that the compound is inhibitory even after the initiation of DNA synthesis. These studies indicate that the ability of BVdUTP to preferentially inhibit the HSV-1 DNA polymerase may contribute towards its selective inhibition of the viral DNA replication in infected cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265902      PMCID: PMC319424          DOI: 10.1073/pnas.78.5.2698

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  DNA synthesis and DNA polymerase activity of herpes simplex virus type 1 temperature-sensitive mutants.

Authors:  G M Aron; D J Purifoy; P A Schaffer
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

2.  Herpesvirus proteins: induction of nucleoside phosphotransferase activity after herpes simplex virus infection.

Authors:  A T Jamieson; J Hay; J H Subak-Sharpe
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

3.  Differences in the ConA-induced redistribution and agglutination patterns of EBV genome-free and EBV-carrying human lymphoma lines.

Authors:  E Yefenof; G Klein; H Ben-Bassat; L Lundin
Journal:  Exp Cell Res       Date:  1977-08       Impact factor: 3.905

4.  Comparative effects on growth and tumorigenicity of mouse melanoma cells by thymidine and its analogs, 5-ethyl- and 5-bromodeoxyuridine.

Authors:  S Silagi; R F Balint; K K Gauri
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

5.  Characterization of herpes simplex virus-induced deoxyribonucleic acid polymerase.

Authors:  A Weissbach; S C Hong; J Aucker; R Muller
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

6.  A virus-specific thymidine kinase in BHK-21 cells infected with herpes simplex virus.

Authors:  H G Klemperer; G R Haynes; W I Shedden; D H Watson
Journal:  Virology       Date:  1967-01       Impact factor: 3.616

7.  DNA-dependent DNA polymerases from HeLa cell nuclei. II. Template and substrate utilization.

Authors:  A Schlabach; B Fridlender; A Bolden; A Weissbach
Journal:  Biochem Biophys Res Commun       Date:  1971-08-20       Impact factor: 3.575

8.  A novel method for phosphorylation of nucleosides to 5'-nucleotides.

Authors:  M Yoshikawa; T Kato; T Takenishi
Journal:  Tetrahedron Lett       Date:  1967-12       Impact factor: 2.415

9.  Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures.

Authors:  C Shipman; S H Smith; R H Carlson; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

10.  Specific herpes simplex virus-induced incorporation of 5-iodo-5'-amino-2',5'-dideoxyuridine into deoxyribonucleic acid.

Authors:  M S Chen; D C Ward; W H Prusoff
Journal:  J Biol Chem       Date:  1976-08-25       Impact factor: 5.157

View more
  37 in total

1.  Identification and some properties of a unique DNA polymerase from cells infected with human B-lymphotropic virus.

Authors:  A R Bapat; A J Bodner; R C Ting; Y C Cheng
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.

Authors:  E M Swierkosz; M Q Arens; K A Rivetna
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

3.  Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus.

Authors:  D M Coen; H E Fleming; L K Leslie; M J Retondo
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

Review 4.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

Review 5.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.

Authors:  O P van Bijsterveld; P J Meurs; E de Clercq; P C Maudgal
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

7.  Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors:  C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

8.  Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides.

Authors:  S A Siegel; M J Otto; E De Clercq; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors:  E de Clercq; Z X Zhang; I S Sim
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

10.  Inhibition of glycosylation of bovine herpesvirus 1 glycoproteins by the thymidine analog (E)-5-(2 Bromovinyl)-2'-deoxyuridine.

Authors:  V Misra; R C Nelson; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.